A trial to evaluate whether encorafenib is safe in Chinese mainland participants with BRAFV600E advanced solid tumors

Ocean I Logo

A multicenter, open-label, phase 1 study investigating the safety and tolerability of encorafenib monotherapy in BRAFV600E-mutated Chinese patients with advanced metastatic solid tumors

Hide study title
Status :
Type of study
Phase I
Min. Age
Years old
Max. Age

Brief summary

Encorafenib is a marketed drug (Braftovi®) approved to treat patients with certain skin cancer (melanoma) and certain colorectal cancer in several countries (European Union, USA, Australia, Japan, Switzerland...).

Limited clinical information of encorafenib used as a single drug (monotherapy) or in combination with other drugs are available specifically in Chinese patients whose tumor has a specific mutation in the BRAF gene (BRAFV600E mutation).

The purpose of this trial is to investigate the safety of encorafenib in Chinese participants with BRAF V600E solid tumors..

Therapeutic area :
Disease :
Advanced solid tumors: skin cancer (melanoma) or lung cancer (non-small cell lung cancer)
Study medication :
Encorafenib (BRAFTOVI®)
Phase : Phase I
Start Date :
15 September 2021
End Date / Planned study Completion Date :
06 May 2022
Study ID : W00090GE102
CT.gov Number : NCT05003622
Countries :

Find out where the clinical trial was conducted ?


Sun Yan-Sen University Cancer Center

651 East Dongfeng Lu
Guangzhou guangdong

Last update at : 15 November 2023

Contact Us

Need more information, click on the button to have access to the contact form.

Contact Us

Access to Lay Protocol Synopsis

Un résumé du protocole rédigé en termes simples et décrivant les objectifs de l’étude vous est proposé.  

Send by email